Monosialotetrahexosylganglioside Sodium

Summary

Monosialotetrahexosylganglioside Sodium (CHEMBL5095280) is a phase-3 clinical-stage unknown; indicated across 2 conditions including gastric neoplasm and colorectal neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095280
Name	Monosialotetrahexosylganglioside Sodium
Type	Unknown
Max phase	3

Also known as: Monosialotetrahexosylganglioside sodium, Sygen, MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02024412	PHASE3	UNKNOWN	Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
NCT02024438	PHASE3	UNKNOWN	Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).